Hormonal
Patients who use anti-obesity medications (AOMs) prior to bariatric surgery experience significant weight regain (average 18 kg) upon stopping the medication, yet this history does not negatively impact their expectations for surgical weight loss.
If you stop taking weight loss drugs like Ozempic before surgery, you will likely regain the weight you lost (average 18kg). However, this history does not mean surgery will fail. Your expectations for surgery should remain focused on long-term health, as your prior drug experience doesn't change your surgical goals or likely success.
Of past AOMs recipients, 87% reported weight regain upon stopping AOMs. Average weight regain was 18 kg (SD 13kg, 126% increase).
Why this rating
Self-reported data from a cross-sectional survey; lacks long-term follow-up or control for confounding lifestyle factors.
Source
Patients experience with preoperative use of anti-obesity medications and associations with bariatric surgery expectations
Jason M. Samuels et al. · Surgery for Obesity and Related Diseases · 2024
DOI 10.1016/j.soard.2024.08.041
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →